Buy the GCP R3 course & get a FREE eBook— your complete ICH-GCP R3 reference guide. Book Now →

  • AI ClinicalAI ClinicalNewRight Arrow
  • Clinical PracticeClinical PracticeRight Arrow
  • PharmacovigilancePharmacovigilanceRight Arrow
  • ManufacturingManufacturingRight Arrow
  • Laboratory PracticeLaboratory PracticeRight Arrow
  • DistributionDistributionRight Arrow
  • Medical DevicesMedical DevicesRight Arrow
  • Regulatory AffairsRegulatory AffairsRight Arrow
  • Research ComplianceResearch ComplianceRight Arrow
  • Health & SafetyHealth & SafetyRight Arrow
  • Quality AssuranceQuality AssuranceRight Arrow
  • All Bundles
  • Clinical Trials Development
  • GCP & GxP Standards
  • Pharmacovigilance
  • Role Based
  • Distribution
  • Medical Devices
  • Medical Writing
  • AI Clinical
View all 21 learning paths
  • Preclinical & Laboratory Foundations Learning Path
  • Phase I – First-in-Human Trials Learning Path
  • Phase II & III – Efficacy & Pivotal Trials Learning Path
  • Clinical Trials Foundation PathNew
  • Regulatory Submission & Approval
Preclinical & Laboratory Foundations Learning Path - courses at £199

About

Nitrosamine Impurities in Pharmaceuticals training provides an overview of nitrosamine impurities, nitrosamine drug substance-related impurities (NDSRIs), regulatory expectations, and risk-based approaches for identifying, assessing, controlling, and mitigating nitrosamine risks throughout the pharmaceutical product lifecycle. It helps learners understand current regulatory guidance, acceptable intake (AI) limits, analytical testing, risk assessment, confirmatory testing, and pharmaceutical quality system requirements.
This Nitrosamine Impurities in Pharmaceuticals Course & Certification provides essential knowledge on nitrosamine formation risk factors, risk evaluation, acceptable intake limits, analytical methods, confirmatory testing, mitigation strategies, change management, documentation, inspection readiness, lifecycle management, and regulatory reporting. Upon successful completion, learners receive a certification demonstrating their understanding of managing nitrosamine risks and maintaining regulatory compliance for pharmaceutical products.

Who Should Enrol?

  • Quality Assurance (QA) Professionals
  • Quality Control (QC) Analysts and Laboratory Personnel
  • Regulatory Affairs Professionals
  • Pharmaceutical Manufacturing and Process Engineers
  • Analytical Development and Validation Scientists
  • Research and Development (R&D) Scientists
  • Compliance, GMP, and Quality Management Professionals
  • Anyone involved in the development, manufacture, testing, or regulatory compliance of pharmaceutical products
📢 Every purchase also includes our FREE companion Nitrosamine Impurities in Pharmaceuticals eBook, designed to help you apply principles in real-world clinical trial settings.

What you will learn

Understand nitrosamine impurities, NDSRIs, their sources, health risks, regulatory expectations, and risk-based approaches for pharmaceutical products.

Learn nitrosamine risk assessment, acceptable intake (AI) limits, analytical testing principles, confirmatory testing, and interpretation of regulatory guidance.

Develop knowledge of nitrosamine risk mitigation strategies, change management, pharmaceutical quality systems (PQS), CAPA, trend analysis, and lifecycle risk management.

Gain understanding of documentation requirements, inspection readiness, regulatory reporting, marketing authorisation updates, and best practices for maintaining compliant pharmaceutical products.

Course Syllabus

  1. Defining nitrosamines and NDSRIs, and the nitrosating agents and vulnerable amines involved
  2. Why nitrosamines are a pharmaceutical quality concern: mutagenic-carcinogen potency at trace levels
  3. Hazard versus exposure versus patient risk — three distinct ideas
  4. The cohort of concern and the TTC framework at a conceptual level (ICH M7(R2))
  5. The global regulatory response: FDA, EMA, MHRA and ICH, and the document TYPE of each
  6. ICH M7(R2) is effective; M7(R3) is forthcoming and not effective
  7. HelixPril: the fictional product and its potential NDSRI risk

  1. Potential sources and formation conditions at a risk-factor level — never a synthetic method
  2. Risks across API, excipient, drug-product and packaging processes
  3. Nitrosating-agent sources such as nitrite in excipients, and vulnerable secondary amines
  4. Cross-contamination and shared-equipment risks
  5. Supply-chain risks: recovered solvents and reagents, route and supplier changes
  6. HelixPril: the excipient with variable nitrite and an API supplier's solvent change
  7. Common failure: treating a formation risk factor as benign

  1. The three-step framework: risk assessment, confirmatory testing and changes
  2. Conducting an initial (risk-evaluation) assessment
  3. Planning confirmatory testing where a risk is identified
  4. Prioritising products across a portfolio using science and patient risk
  5. Documenting conclusions and the uncertainty that remains
  6. HelixPril: prioritising the portfolio and documenting the initial assessment
  7. Common failure: an assessment that hides its uncertainty

  1. Defining an appropriate analytical strategy (for example LC-MS/MS) for the target analyte
  2. Sensitivity, specificity and method suitability relative to the acceptable intake
  3. Detection (LOD) versus quantitation (LOQ) versus specification versus acceptable intake (AI)
  4. Interpreting results and uncertainty, including OOS and OOT
  5. Managing third-party laboratories and sample and batch representativeness
  6. HelixPril: planning and interpreting the confirmatory LC-MS/MS testing
  7. Common failure: confusing an analytical limit with a health-based limit

  1. Interpreting published acceptable-intake limits with source, date, jurisdiction and compound
  2. Compound-specific and class-based (CPCA) approaches, and the Enhanced Ames Test
  3. Applying potency categorisation conceptually (the five CPCA categories)
  4. Evaluating multiple nitrosamines and exposure scenarios, including less-than-lifetime
  5. The AI-to-ppm conversion using the maximum daily dose, and the verify-before-use rule
  6. HelixPril: a CPCA-category AI superseded by a compound-specific study
  7. Common failure: extrapolating one compound's AI to another without a justified method

  1. Selecting proportionate mitigation across API, formulation, process and packaging
  2. Designing a control strategy that links each control to the risk it addresses
  3. Assessing process, formulation and packaging changes for their impact on nitrosamine risk
  4. Regulatory submission implications: variations, recall or shortage, and CAPA
  5. The regulatory-action decision tree from finding to proportionate response
  6. HelixPril: mitigation, a variation, change control and CAPA
  7. Common failure: a control not matched to the risk, or a change not assessed

  1. Maintaining an effective lifecycle programme — risk assessment is not a one-off
  2. Integrating nitrosamine controls into the pharmaceutical quality system
  3. Preparing traceable evidence for inspections and audits
  4. Responding to new scientific and regulatory information (horizon scanning)
  5. Recognising when specialist toxicological, analytical or regulatory support is required
  6. HelixPril: monitoring, effectiveness checks and inspection readiness
  7. Common failure: a programme that stops after the first negative result

  1. The end-to-end journey and what a good programme looks like
  2. The eight discipline rules, restated
  3. Common errors and how to avoid them
  4. A practical implementation checklist and learner action plan
  5. Final-assessment preparation and certificate requirements

  1. 📘 Bonus: Nitrosamine Impurities in Pharmaceuticals eBook (Free with purchase)

Course Benefits

Benefits ebook icon
Free eBook

Get our exclusive eBook with every purchase - a complete companion guide to the course, yours to keep forever

Benefits cpd_points icon
CPD Points

Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.

Benefits certification icon
Certification

Receive a personal certificate to show your subject knowledge on course completion.

Benefits affordable icon
Affordable

You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.

Benefits flexible icon
Flexibility

The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.

Benefits up_to_date icon
Keep Up to Date

You will stay up to date with the current effective nitrosamine sources and their document TYPE: the FDA guidance Control of Nitrosamine Impurities in Human Drugs (Revision 2, September 2024) and Recommended Acceptable Intake Limits for NDSRIs (final August 2023, with the CPCA and the published RAIL list updated January 2025) — non-binding US guidance; ICH M7(R2), effective since 2023 (with M7(R3) in development and NOT effective, taught only as forthcoming) — an effective ICH standard; the EMA/CHMP Article 5(3) nitrosamines Q&A (Revision 23, October 2025) with Appendix 1 (updated December 2025) and the MHRA GOV.UK guidance (April 2024 update) — non-binding EU and UK guidance; EDQM pharmacopoeial / CEP procedure; WHO good practice; and ICH Q3A/Q3B and Q9(R1). Every acceptable-intake value is stated with its source, date, jurisdiction and compound, and must be re-verified at the cited register before use. Source positions were verified in July 2026 and are monitored, reviewed and updated.

Benefits industry_experts icon
Learn from Industry Experts

The course content is Whitehall Training editorial material, developed to reflect established pharmaceutical-quality practice in the identification, assessment, prevention and control of nitrosamine impurities — and the failure modes that appear when a control is not matched to a risk, an acceptable intake is misapplied, or a programme stops after one negative result. It is built around a single fictional case study, HelixPharm International and HelixPril, with a canonical set of suppliers, materials, scenarios and changes, so that every risk-assessment, testing, acceptable-intake, mitigation and lifecycle decision in the course is one the learner can reason through. Sources are paraphrased and section-referenced; they are never reproduced, and no synthetic detail of any kind is given.


Our Certified Customers

novartis
NHS
takeda
roche
dhl

Learner Rating & Reviews

4.7
★★★★★★
Average Rating
536 global ratings
★★★★★
87.0%
★★★★★
5.0%
★★★★★
3.0%
★★★★★
3.0%
★★★★★
2.0%
RC

Working with Whitehall training for the last two years of partnership has been a very successful experience – I have fast access to all the GCP course...

SM

I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...

Recommended Courses

Essentials of EU MDRBest Seller

Essentials of EU MDR

Professional
£493 hrs3 points
Good Clinical Laboratory Practice (GCLP)Best Seller

Good Clinical Laboratory Practice (GCLP)

Intermediate
£796 hrs6 points
21 CFR Part 58 — Good Laboratory Practice (GLP) for Nonclinical Laboratories

21 CFR Part 58 — Good Laboratory Practice (GLP) for Nonclinical Laboratories

Intermediate
£393 hrs2 points
Risk Management for Medical Devices ISO 14971:2019

Risk Management for Medical Devices ISO 14971:2019

Intermediate
£393 hrs2 points
Computer System Validation - Validation, Data Integrity & Compliance (GAMP 5 & Annex 11)

Computer System Validation - Validation, Data Integrity & Compliance (GAMP 5 & Annex 11)

Intermediate
£393 hrs2 points